Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Cosmo Pharmaceuticals : announces Canadian Agency approval of Eleview for endoscopic resections of polyps

share with twitter share with LinkedIn share with facebook
share via e-mail
07/02/2019 | 09:52am EDT

Dublin - Cosmo Pharmaceuticals N.V. (SIX: COPN), a specialty pharmaceutical company leader in the field of selected gastrointestinal disorders and endoscopy, announced today that Health Canada has approved Eleview, a sub-mucosal injectable formulation used to facilitate the removal of colonic lesions more safely and quickly.

Eleview will be commercialized in Canada by Pendopharm (Division of Pharmascience Inc.) under an existing license and supply agreement. Eleview already is approved and marketed in the US and EU.

'Approval from Health Canada further expands the geographic reach of this innovative product, providing this new market with an important tool to help removal of mucosal lesions during an endoscopy. We are looking forward to Eleview sales in Canada and U.S. as Pharmascience and our U.S. partner, Medtronic, leverage their well-established marketing organizations.' said Alessandro Della Cha, CEO of Cosmo Pharmaceuticals.

Eleview is a blue injectable liquid composition that is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to removal with a snare or other endoscopic device. Eleview also assists the endoscopist performing the resection procedure by visualizing the margins of the target lesion, thereby decreasing the risk of incomplete resection and potential perforation.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam.


John Manieri

Tel: +353 (1) 8170 370

Email: jmanieri@cosmopharma.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an 'offer of securities to the public' within the meaning of Directive 2003/71/EC of the European Union (the 'Prospectus Directive') of the securities referred to in it (the 'Securities') in any member state of the European Economic Area (the 'EEA'). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
07/30Cosmo Half-Year Report 2019
07/05Cosmo Pharmaceuticals Posts GI Genius Video Demonstration at Image 2019 Confe..
07/02COSMO PHARMACEUTICALS : announces Canadian Agency approval of Eleview for endosc..
07/01Cosmo Pharmaceuticals announces Canadian Agency approval of Eleview® for endo..
06/24COSMO PHARMACEUTICALS : announces Publication of Review of Aemcolo as Treatment ..
06/21Cosmo Pharmaceuticals announces Publication of Review of Aemcolo™ as Tr..
06/11COSMO PHARMACEUTICALS : N.V. - FDA accepts filing of NDA for Remimazolam
06/10FDA accepts filing of NDA for Remimazolam
05/29COSMO PHARMACEUTICALS' : Shareholders approve all Agenda Items at Annual General..
05/28Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annual Genera..
More news
Financials (EUR)
Sales 2019 56,0 M
EBIT 2019 -22,9 M
Net income 2019 -32,9 M
Finance 2019 146 M
Yield 2019 -
P/E ratio 2019 -31,3x
P/E ratio 2020 -96,8x
EV / Sales2019 15,5x
EV / Sales2020 8,90x
Capitalization 1 016 M
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 119,62  €
Last Close Price 69,45  €
Spread / Highest target 131%
Spread / Average Target 72,2%
Spread / Lowest Target 20,2%
EPS Revisions
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287